Bristol's Sale Of HIV Pipeline To ViiV Signals Tightened Focus
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb Co. on Dec. 18 took another step in narrowing its therapeutic focus by selling its pipeline of HIV candidates, including novel Phase III and Phase IIb assets, to ViiV Healthcare in a pair of deals bringing $350m in upfront cash and significant earn-out potential back to the US-based pharma.
You may also be interested in...
How Will Novel Agents Impact The HIV Market?
ViiV and Merck are looking to novel mechanisms of action as an opportunity to make up ground on HIV leader Gilead, which has de-emphasized early virology research.
Bristol Changes Up R&D But Not Backing Down On Oncology
The appointment of oncologist Thomas Lynch to succeed Francis Cuss as Chief Scientific Officer suggests the biopharma won’t be straying too far from its current focus on developing cancer drugs.
Novel Antibody Products Ring The Treatment Changes In HIV
Two Canadian companies – Theratechnologies and CytoDyn – exploring the use of monoclonal antibodies in the fight against HIV presented data for their novel late-stage candidates at the recent CROI meeting in Seattle. They are aimed at patients experiencing multi-drug resistance and represent a change in this mature therapy area dominated by small-molecule oral products.